KETOROLAC HIGH GASTRIC ULCER INCIDENCE SHOULD BE WEIGHED IN SHORT-TERM THERAPY

KETOROLAC HIGH GASTRIC ULCER INCIDENCE SHOULD BE WEIGHED IN SHORT-TERM THERAPY, according to the authors of a study to be published in the January issue of Epidemiology. The study, "Gastroduodenal toxicity of different nonsteroidal anti- inflammatory drugs," by researchers Giuseppe Traversa, Instituto Superiore di Sanua, Rome, Alexander Walker, Harvard School of Public Health, et al., concluded that the "use of ketorolac appears to carry a greater gastrotoxicity than other NSAIDs." Syntex markets ketorolac in oral and intramuscular forms as Toradol.